Dirk Waldschmidt

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

Marianne Sinn, Marcus Bahra, Torsten Liersch et al. · Journal of Clinical Oncology · 2017 · 296 citations

Medicine, Oncology, Pharmacotherapy +13

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Algül et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 197 citations

Medicine, Oncology, Pharmacology +10

Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma

Katharina Leuchte, E Staib, Martin Thelen et al. · Cancer Immunology Immunotherapy · 2020 · 138 citations · Full text

Life Sciences, Immunology, Oncology +17